- Home
- TTSH vs ZNTL Comparison
TTSH vs ZNTL Comparison
Compare TTSH & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTSH
- ZNTL
- Stock Information
- Founded
- TTSH 1985
- ZNTL 2014
- Country
- TTSH United States
- ZNTL United States
- Employees
- TTSH N/A
- ZNTL N/A
- Industry
- TTSH Blank Checks
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- TTSH Finance
- ZNTL Health Care
- Exchange
- TTSH Nasdaq
- ZNTL Nasdaq
- Market Cap
- TTSH 275.5M
- ZNTL 105.8M
- IPO Year
- TTSH N/A
- ZNTL 2020
- Fundamental
- Price
- TTSH $6.36
- ZNTL $1.20
- Analyst Decision
- TTSH
- ZNTL Buy
- Analyst Count
- TTSH 0
- ZNTL 7
- Target Price
- TTSH N/A
- ZNTL $8.60
- AVG Volume (30 Days)
- TTSH 70.2K
- ZNTL 1.4M
- Earning Date
- TTSH 08-07-2025
- ZNTL 08-08-2025
- Dividend Yield
- TTSH N/A
- ZNTL N/A
- EPS Growth
- TTSH N/A
- ZNTL N/A
- EPS
- TTSH 0.01
- ZNTL N/A
- Revenue
- TTSH $343,352,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- TTSH N/A
- ZNTL N/A
- Revenue Next Year
- TTSH N/A
- ZNTL N/A
- P/E Ratio
- TTSH $378.59
- ZNTL N/A
- Revenue Growth
- TTSH N/A
- ZNTL N/A
- 52 Week Low
- TTSH $4.62
- ZNTL $1.01
- 52 Week High
- TTSH $7.75
- ZNTL $5.44
- Technical
- Relative Strength Index (RSI)
- TTSH 52.73
- ZNTL 43.44
- Support Level
- TTSH $5.89
- ZNTL $1.31
- Resistance Level
- TTSH $7.00
- ZNTL $1.39
- Average True Range (ATR)
- TTSH 0.28
- ZNTL 0.13
- MACD
- TTSH 0.03
- ZNTL -0.02
- Stochastic Oscillator
- TTSH 42.34
- ZNTL 6.83
About TTSH Tile Shop Holdings Inc.
Tile Shop Holdings Inc is a specialty retailer of natural stone and man-made tiles, setting and maintenance materials, and related accessories in the United States. It manufactures its setting and maintenance materials, such as thinset, grout, and sealers. The company's primary market is retail sales to consumers, contractors, designers and home builders. Natural stone products include marble, travertine, granite, quartz, sandstone, slate, and onyx tiles. Man-made products include ceramic, porcelain, glass, cement, wood look, metal and luxury vinyl tile.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.